Announcements Trials
Browse Landscape

Phase

Phase 2 3

Status

Active not recruiting 3

Sponsor Class

OTHER 2NIH 1

Study Type

Interventional 3

Sponsor

Cancer Type

Sarcoma 3Head & Neck 1Gynecologic 1Endocrine 1Breast 1

Conditions

Melanoma 11Carcinoma, Renal Cell 10Carcinoma, Non-Small-Cell Lung 6Prostatic Neoplasms 4Neoplasm Metastasis 4Myelodysplastic Syndromes 4Lung Neoplasms 4Clear-cell metastatic renal cell carcinoma 4Urinary Bladder Neoplasms 3Urethral Neoplasms 3Leukemia, Myeloid, Acute 3Histiocytoma, Malignant Fibrous 3Carcinoma, Transitional Cell 3Carcinoma, Basal Cell 3Urogenital Neoplasms 2Ureteral Neoplasms 2Thyroid Neoplasms 2Sarcoma 2Penile Neoplasms 2Ovarian Neoplasms 2Nasopharyngeal Carcinoma 2Glioblastoma 2Carcinoma, Merkel Cell 2Carcinoma, Endometrioid 2Brain Neoplasms 2Adenocarcinoma of Lung 2Vulvar Neoplasms 1Uveal Melanoma 1Urachal adenocarcinoma 1Triple Negative Breast Neoplasms 1

Interventions

Specimen Handling 4Radiotherapy 4Radiation 4Nivolumab 4pembrolizumab 3Magnetic Resonance Spectroscopy 3Ipilimumab 3Doxorubicin 3CTLA-4 Antigen 3Biopsy 3talimogene laherparepvec 1peposertib 1pazopanib 1liposomal doxorubicin 1fludarabine 1cabozantinib 1aldesleukin 1X-Rays 1Trabectedin 1Ifosfamide 1Histamine H2 Antagonists 1Famotidine 1Dactinomycin 1Cyclophosphamide 1BO-112 1Angptl4 protein, mouse 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
Histiocytoma, Malignant Fibrous × CTLA-4 Antigen × 90 days × Clear all
NCT03449108 2026-05-22

LN-145 or LN-145-S1 in Treating Patients With Relapsed or Refractory Ovarian Cancer, Triple Negative Breast Cancer (TNBC), Anaplastic Thyroid Cancer, Osteosarcoma, or Other Bone and Soft Tissue Sarcomas

M.D. Anderson Cancer Center

Phase 2 Active not recruiting
30 enrolled
BreastEndocrineGynecologicHead & NeckSarcoma

Bone Neoplasms, Ovarian Neoplasms, Sarcoma, Osteosarcoma, Giant Cell Tumor of Bone, Histiocytoma, Malignant Fibrous, Triple Negative Breast Neoplasms, Thyroid Carcinoma, Anaplastic

NCT05836571 2026-04-21

Testing Ipilimumab and Nivolumab Combination With or Without Cabozantinib in People >= 18 Years Old With Advanced Soft Tissue Sarcoma

National Cancer Institute (NCI)

Phase 2 Active not recruiting
66 enrolled
Sarcoma

Sarcoma, Histiocytoma, Malignant Fibrous

NCT03307616 2026-03-05

Nivolumab With and Without Ipilimumab and Radiation Therapy in Treating Patients With Recurrent or Resectable Undifferentiated Pleomorphic Sarcoma or Dedifferentiated Liposarcoma Before Surgery

M.D. Anderson Cancer Center

Phase 2 Active not recruiting
32 enrolled
Sarcoma

Liposarcoma, Histiocytoma, Malignant Fibrous

Data powered by HemOnc (CC BY 4.0) Colophon âš¡